A synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory activities.
Betamethasone binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.
Allergic and inflammatory disorders; congenital adrenal hyperplasia 0.5-5 mg/day.
Allergic and inflammatory disorders - betamethasone Na phosphate and betamethasone acetate: Initial: 0.25-9 mg/day in 1-2 divided doses.
Allergic and inflammatory conditions of the eye - 0.1% soln: As Na phosphate: instill 1-2 hrly until symptoms are controlled. - 0.1% oint: As Na phosphate: apply 2-4 times/day or at night w/ the eye drops
Topical skin disorders - dipropionate (0.05%) or valerate (0.025 or 0.1%): apply as directed.
Adverse drug reactions: sodium and fluid retention, potassium and calcium depletion. Muscle wasting, weakness, osteoporosis. GI disturbances and bleeding. Increased appetite and delayed wound healing; hirsutism, bruising, striae, acne; raised intracranial pressure, headache, depression, psychosis, menstrual irregularities. Hyperglycaemia